In summary, IL-17A and IL-22 are particularly significant among type 3 cytokines due to the wide investigation of their roles in the initiation, progression, and resolution of liver disease, notably MASLD, and their therapeutic potential and will thus be the focus of this review. Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.